Venomics AI raises $2.7 million to find medicines in animal venom
By Anika SharmaAI & Innovations Editor, Peepals Tech
Representative image: trank / Pixabay
IISc spin-out Venomics AI raised $2.7 million pre-seed, co-led by Speciale Invest and South Park Commons, announced 5 November 2026, for AI venom drug discovery.
What Happened
Venomics AI, a Bengaluru biotechnology start-up spun out of the Indian Institute of Science (IISc), has raised $2.7 million in a pre-seed round to use artificial intelligence to find new medicines in animal venom. The round, announced on Thursday, 5 November 2026, was co-led by Speciale Invest and South Park Commons, with Operators Studio also taking part. It is the company's first institutional funding. Venomics AI was co-founded by Kartik Sunagar, an IISc professor whose research covers venom evolution and antivenom development, and Vinay Prabhu, its chief technology officer.
Key Facts
- Company: Venomics AI, Bengaluru, a spin-out from the Indian Institute of Science.
- Round: $2.7 million pre-seed, the company's first institutional funding.
- Investors: co-led by Speciale Invest and South Park Commons, with participation from Operators Studio.
- Founders: Kartik Sunagar, IISc professor, and Vinay Prabhu, chief technology officer, who holds a PhD from Carnegie Mellon University.
- Core asset: the Venom Atlas, a database of venom molecules built from molecular sequencing and venom biology.
- Method: AI ranks and prioritises candidate molecules from the Atlas, which are then tested through laboratory screening.
- Use of funds: expanding the Venom Atlas, strengthening AI-led discovery and lab screening, and validating potential drug candidates.
- Note: the company's own website lists a $2.7 million funding milestone in April 2026, so the round may have closed earlier than its public announcement.
Why It Matters
Venoms from snakes, spiders, scorpions, cone snails and other animals are mixtures of highly active molecules that evolved to act quickly and precisely on the body's nerves, blood and muscles. That precision is what makes some of them interesting as starting points for medicines. The search for such molecules has traditionally been slow, because each venom contains many different compounds and testing them one by one in the lab takes years.
Venomics AI's approach is to first catalogue venom molecules at scale in a database, then use machine learning, a type of AI that learns patterns from data, to predict which molecules are most likely to act on a given disease target. Only the most promising candidates go to the lab. If the predictions are good, this narrows the search and can save time and money. The company's claims about its platform have not yet been tested in clinical trials; at this pre-seed stage, it is building the database and early evidence.
The start-up also reflects a pattern in Indian deep-technology: companies spun out of research institutions such as IISc, turning years of academic work into products. Sunagar's lab works on venom and antivenom; in September, researchers from IISc and the Technical University of Denmark published work in Science Translational Medicine on a nanobody-based antivenom that protected mice against venom from several cobra species found in India. That antivenom research is academic work, not a Venomics AI product.
Peepals timeline: Kartik Sunagar's IISc lab built its expertise in venom evolution and antivenom over several years. In April 2026, according to the company's website, Venomics AI recorded a $2.7 million funding milestone. In September 2026, IISc and Danish researchers published their nanobody antivenom study. On 5 November 2026, the $2.7 million pre-seed round co-led by Speciale Invest and South Park Commons was publicly announced.
| Venomics AI funding | Detail |
|---|---|
| Amount | $2.7 million |
| Stage | Pre-seed (first institutional round) |
| Lead investors | Speciale Invest, South Park Commons (co-leads) |
| Other investor | Operators Studio |
| Base | Bengaluru (IISc spin-out) |
Impact
Short-term: The money pays for a larger Venom Atlas, more AI work and more lab screening, which should produce the company's first validated drug candidates.
Long-term: If its candidates hold up in testing, Venomics AI could license molecules to drug companies or develop its own, adding to India's small but growing field of AI-led drug discovery.
Who is affected: Researchers in venom biology and drug discovery, Indian deep-tech investors, IISc's spin-out ecosystem, and, in the long run, patients if any candidate becomes a medicine.
Key Takeaway
IISc spin-out Venomics AI has raised $2.7 million, co-led by Speciale Invest and South Park Commons, to use AI to find drug candidates in animal venom.
Questions and Answers
How much did Venomics AI raise?
Venomics AI raised $2.7 million in a pre-seed round announced on 5 November 2026, co-led by Speciale Invest and South Park Commons, with Operators Studio taking part.
What does Venomics AI do?
The Bengaluru start-up builds a database of venom molecules, the Venom Atlas, and uses AI to pick the molecules most likely to work as medicines, which it then tests in the lab.
Who founded Venomics AI?
IISc professor Kartik Sunagar, who studies venom evolution and antivenoms, and chief technology officer Vinay Prabhu, who holds a PhD from Carnegie Mellon University.
Has Venomics AI made a drug yet?
No. It is at an early stage, building its database and screening candidates. None of its molecules has been reported as tested in people.
Disclaimer: Prepared by the Peepals newsroom from publicly available sources with AI assistance. Information is accurate to the best of our knowledge at the time of publication and may change. Images may be representative. Not professional advice. Report an error via our contact page.
By Anika Sharma, AI & Innovations EditorCovers AI & Innovation and more for Peepals Tech. All stories by Anika Sharma
Mercedes-Benz GLC EV launched at Rs 78.5 lakh, made in Pune
Tesla FSD South Korea complaint: consumers say China-built cars cannot use it
Get the day's stories in your inbox
Peepals Weekly: the week decoded, free. One email a week, unsubscribe in one click.
Anika Sharma is a pen name of the Peepals Global Editorial Team, which researches, fact-checks and publishes every story. The portrait is an illustration.
